News | January 21, 2026
Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Winlevi is authorized in EU for the treatment of acne vulgaris
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Venus Remedies now has 29 active product approvals in Vietnam alone
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
